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The development of T-cell-based immunotherapies of cancer largely depends on the availability of tumour-associated antigens
capable of eliciting tumour-directed cytotoxic T-cell responses. In prostate cancer, the number of antigens defined as suitable targets
of cytotoxic T lymphocytes (CTLs) is still limited. Recently, prostein was identified as a transmembrane protein that is highly restricted
to prostate tissues. In our study, prostein transcripts were found to be abundant in both malignant and nonmalignant prostate tissue
samples. To identify immunogenic CD8þ T-cell epitopes, human leucocyte antigen-A*0201-binding peptides were selected from
the amino-acid sequence of prostein and were used for the in vitro stimulation of CD8þ T lymphocytes. Specific CTLs were raised
against the prostein-derived peptide CLAAGITYV that were capable of lysing prostate cancer cells, indicating that this peptide is
naturally generated by tumour cells. Our data suggest that prostein is a suitable candidate to be included in a T-cell-based
immunotherapy of prostate cancer.
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Prostate carcinoma (PCa) is the most common cancer diagnosis
and the second leading cause of cancer-related deaths in men
(Howe et al, 2001). The absence of effective curative therapies for
advanced and recurrent prostate tumours has entailed an intensive
search for novel treatment modalities.
T cells provide a powerful compartment of adaptive immunity
with the potential to survey and respond to a great diversity of
antigens. The immunotherapy of human tumours has been put
forward by the finding that CD8þ cytotoxic T lymphocytes
(CTLs) are capable of effective recognition and destruction of
tumour cells (Rosenberg, 1997). Consequently, much attention has
been paid to the identification and characterisation of tumour-
associated antigens (TAAs) that may provide target structures for a
T-cell-based vaccination strategy (Saffran et al, 1999; Nelson,
2002).
While searching for new potential immunotherapeutic targets of
PCa, a number of prostate- or PCa-associated transcripts and
proteins have been identified during the last years such as six-
transmembrane epithelial antigen of the prostate (Hubert et al,
1999), prostase (Nelson et al, 1999), prostate androgen-regulated
transcript 1 (PART-1) (Lin et al, 2000), human novel prostate-
specific antigen (PSA) (Naz et al, 2002), human prostate-specific
gene-1 (Herness and Naz, 2003) and NKX3.1 (He et al, 1997).
However, recent observations suggest that the expression of some
of these molecules is not strictly confined to prostate tissue
(Hubert et al, 1999; Yousef et al, 1999; Sidiropoulus et al, 2001).
The suitability of these molecules for T-cell-based immunotherapy
is limited, since targeting epitopes that are presented on essential
tissues may induce adverse autoimmune reactions. Other mole-
cules are downregulated in tumour tissue when compared with
normal prostate tissue (Bowen et al, 2000; Xu et al, 2003).
The high diversity, the genetic instability and the escape
mechanisms of tumours determine the number of individual
target structures for T-cell-based immunotherapeutic strategies. In
addition, the number of prostate-specific proteins known to elicit
T-cell responses is still limited. Therefore, the identification of new
TAAs can facilitate T-cell-based vaccination strategies in PCa
patients. The efficiency of the antitumour response could be
increased by including a collection of well-characterised epitopes
derived from diverse antigens for the activation of patients’ T cells.
Recently, prostein was identified as a novel prostate-specific
protein using a cDNA library substraction strategy (Xu et al, 2001).
The expression of prostein is highly restricted to malignant and
nonmalignant prostate tissues at both mRNA and protein level.
Having confirmed the expression of prostein in normal and
malignant prostate tissues by real-time PCR, we investigated the
suitability of prostein to serve as a target antigen for PCa-directed
CTLs. An immunogenic human leucocyte antigen (HLA)-A*0201-
restricted peptide derived from prostein was identified, which
proved to be effective in activating tumour-directed CTL
responses. The newly identified peptide may be appropriate to
be included as a target structure in a T-cell-based immunotherapy
of patients with HLA-A*0201-positive PCa.
MATERIAL AND METHODS
Cell lines
The PCa cell lines LNCaP 1740 and PC-3, the mutant cell line T2
and the chronic myelogenous leukemia cell line K562 (all from
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yAmerican Type Culture Collection, Manassas, VA, USA) were
cultured according to the manufacturer’s instructions. The
melanoma cell line 93.04A12.1 was kindly provided by Dr CJM
Melief (University Hospital, Leiden, The Netherlands). This cell
line was maintained in RPMI 1640 medium (Biochrom, Berlin,
Germany) supplemented with 2mML -glutamine, 1% nonessential
amino acids (both from Biochrom), 100mgml
 1 penicillin,
100mgml
 1 streptomycin (both from Life Technologies, Karlsruhe,
Germany) and 10% heat inactivated foetal calf serum (FCS)
(Biochrom).
The androgen deprivation and stimulation experiments were
performed as described previously (Xu et al, 2001). Briefly, LNCaP
1740 cells were cultured for 24h in phenol red-free RPMI (Life
Technologies) supplemented with 1% nonessential amino acids,
10mM HEPES (Life Technologies) and 10% charcoal-stripped FCS
(Biochrom). The cultivation was continued for additional 48h in
the androgen-depleted medium or in the presence of 1nM of the
synthetic androgen R1881 (Perkin-Elmer Life Sciences, Rodgau-
Ju ¨gesheim, Germany). Subsequently, the cells were harvested and
were used as target cells in a chromium release assay.
Prostate cancer patients and tissue samples
All tissue and blood samples were obtained from prostatectomised
PCa patients and healthy donors with informed consent. All
samples from PCa patients were obtained together with clinical
data and pathological classification (Table 1). We analysed pairs of
tissue samples (specimens of primary PCa and autologous
nonmalignant prostate tissue) from 15 patients.
RNA isolation and cDNA synthesis
Total RNA was extracted by standard procedures (Trizol LS
Reagent; Life Technologies, Karlsruhe, Germany) and quality was
analysed by agarose-gel electrophoresis. After DNA digestion
(DNase I; Amersham Pharmacia Biotech, Freiburg, Germany),
cDNA synthesis was performed using 4mg of total RNA and
random hexamer primers (Ready to Go You Prime First Strand
Kit; Amersham Pharmacia Freiburg Biotech, Germany).
Quantitative reverse transcription (RT)–PCR
The mRNA quantity of prostein was determined using a Light-
Cycler (LC)-based real-time PCR protocol based on SYBR Green I
detection (LC – FastStart DNA Master SYBR Green I; Roche
Diagnostics, Mannheim, Germany) and the primer pair Pros-
tein_N1 (50-AACCTTTGGCCTGGAGGTGTGTTTG-30) and Pros-
tein_C1 (50-GGGATGAGAAAGAGGCTCAGCAGGA-30) to amplify
a 240bp cDNA fragment spanning two exons.
The mRNA copy number was adjusted to the RT–PCR product
quantity of hypoxanthine phosphoribosyltransferase (HPRT)
determined by LC technique using the primer pair HPRT_N1
(50-CCCTGGCGTCGTGATTAGTGATGAT-30) and HPRT_C1 (50-
TGCTTTGATGTAATCCAGCAGGTCAGC-30) for the amplification
of a 238bp fragment.
Serial dilutions of plasmid DNA containing the prostein or
HPRT fragments over six log scales (10
1–10
6
moleculescapillary
 1), allowing the linear regression of the cross-
ing points vs the logarithm of sample concentration (regression
coefficient:  1.00; mean squared error: o0.15), were used as
internal template standards for the calculation of the transcript
copy number (calculation via fit point mode of the LC quantifica-
tion software version 3.5; Roche Diagnostics, Mannheim, Ger-
many). The detection limit of the assays was 10 transcript copies.
Each determination was carried out twice for each cDNA sample.
From the mean values, the molecule ratios of prostein to HPRT
transcripts were calculated.
Epitope prediction and peptide synthesis
Potential HLA-A*0201 ligands were selected from the amino-acid
sequence of prostein (accession no. NP_149093) using a matrix
pattern suitable for the calculation of peptides fitting to an HLA-
A*0201 motif (Rammensee et al, 1999; http://www.syfpeithi.de).
This scoring system allows the prediction of the binding affinity of
a given peptide to HLA-A*0201 by evaluating each amino acid
within the sequence for their preference in the respective position.
The allocation of values is based on the frequency of the respective
amino acid in known natural ligands, T-cell epitopes or binding
peptides. The six highest scoring peptides were synthesised as
described previously (Kiessling et al, 2002).
Competition assay
Binding studies of potential HLA-A*0201 fitting peptides were
carried out using the B-cell lines LCL721 or JY and a fluorescence-
based competition assay, essentially as described by van der Burg
et al (1995), but without performing acid strip. Reporter peptide
Table 1 Pathological and clinical parameters (UICC TNM classification system from 1997) and the percentage of tumour cells in tissue samples analysed
by real-time PCR
Patient Age (years)
a
TNM
classification G GS
Percentage of tumour cells (%)
b
malignant/nonmalignant sample
1 62 pT2 pN0 cM0 IIb 7 60/0
2 62 pT2a pN0 cM0 NA NA 70/0
3 63 pT2b pN0 cM0 IIb 6 85/0
4 61 pT2b pN0 cM0 IIIb 8 100/0
5 62 pT2b pN0 cM0 IIa 7 80/0
6 63 pT2b pN0 cM0 IIIa 7 90/0
7 59 pT2b pN0 cM0 IIb 7 85/10
8 60 pT2b pN0 cM0 IIb 6 80/0
9 66 pT3 pN0 cM0 NA 8 95/0
10 71 pT3b pN1 cM0 IIIa 7 70/0
11 59 pT3a pN0 cM0 IIIb 9 95/0
12 73 pT3a pN0 cM0 IIIa 8 80/0
13 58 pT4 pN0 cM0 IIb 7 75/0
14 61 pT4 pN0 cMx IIb 6 75/0
15 57 pT4 pN1 cM0 IIIb 9 75/0
aAt the time point of prostatectomy.
bPercentage of tumour cells within the epithelial cells. G, tumour grade; GS, Gleason score; N, lymph node metastases; NA, not available; p,
pathological examination; T, tumour stage.
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positive control was YLLPAIVHI from RNA helicase p72.
Fluorescence intensities were recorded by flow cytometry (FACS-
CALIBUR; Becton Dickinson, Heidelberg, Germany).
In vitro generation of prostein-specific CD8þ cytotoxic T
lymphocytes
Briefly, peripheral blood mononuclear cells were prepared from
blood samples by Ficoll–Hypaque (Biochrom) density centrifuga-
tion. Monocytes were isolated by immunomagnetic cell separation
with an anti-CD14 antibody coupled to paramagnetic microbeads
(Miltenyi Biotech, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. Mature monocyte-derived dendritic
cells (DCs) were generated as described previously (Schmitz et al,
2000).
To generate prostein-specific CTLs, mature DCs were either
pulsed with a cocktail of the prostein-derived peptides 1478, 1479
and 2004 or a cocktail of the peptides 1472, 1487 and 1494 at a
concentration of 20mgml
 1 of each peptide in serum-free RPMI
1640 medium for 3h. After washing 2 10
5 peptide-loaded DCs
were cocultured with 2 10
6 immunomagnetically isolated CD8þ
T cellswell
 1 of a 24-well tissue culture plate (Greiner, Frick-
enhausen, Germany). T-cell cultures stimulated with DCs pulsed
with the peptides 1478, 1479 and 2004 were established from two
prostate cancer patients (donors 1 and 3) and a healthy individual
(donor 2). The peptides 1472, 1487 and 1494 were used to stimulate
an additional culture of donor 2 and T cells obtained from another
patient (donor 4). The T cells were cultured in 2ml RPMI 1640
mediumwell
 1 supplemented with 10% human serum (CCpro,
Neustadt, Germany), 100Uml
 1 IL-2 and 10ngml
 1 IL-7 (both
from Strathmann Biotech, Hanover, Germany). After 7 days,
cultures were washed and restimulated with peptide-loaded DCs at
a responder to stimulator ratio of 5:1. After three rounds of
weekly restimulation, the cultures were tested for the presence of
prostein-specific CTLs.
Chromium release assay
Cytotoxic activity of the in vitro-stimulated CTLs was assayed
against the HLA-A*0201-positive mutant cell line T2 pulsed with
the individual prostein-derived peptides or an irrelevant HLA-
A*0201-binding peptide from HIV-1 reverse transcriptase at a
concentration of 50mgml
 1, against the PCa cell line LNCaP 1740,
the melanoma cell line 93.04A12.1 and against K562 cells as targets
in a 4h standard
51Cr release assay as described previously
(Kiessling et al, 2002). The HLA-A2 restriction of CD8þ T-cell-
mediated lysis was tested at an effector cell to target cell ratio of
30:1 in the presence of the anti-HLA-A2 monoclonal antibody
derived from the MA2.1 hybridoma (American Type Culture
Collection) at a final concentration of 1mgml
 1.
Flow cytometry
To evaluate the expression of HLA-A2 on the tumour cell lines
used as target cells in the chromium release assays, LNCaP 1740
cells and the melanoma cell line 93.04A12.1 were harvested and
resuspended in FACS buffer (phosphate-buffered salineþ0.05%
sodium acid). Thereafter, the cells were incubated with the anti-
HLA-A2 monoclonal antibody MA2.1 or an isotype-matched
control antibody (Mouse IgG1; BD Pharmingen, San Diego, CA,
USA) both at a concentration of 10mgml
 1 and stained with a PE-
labelled goat anti-mouse IgG F(ab0)2 fragment (Beckman Coulter,
Krefeld, Germany), followed by flow cytometric analysis. To verify
the specificity of MA2.1, the HLA-A2-negative PCa cell line PC-3
was included in the FACS analysis (Figure 3C).
RESULTS
Quantitative assessment of prostein mRNA expression in
prostate tissue specimens
Paired malignant and nonmalignant prostate tissue specimens
obtained from 15 patients with histologically confirmed PCa were
analysed for prostein expression using the quantitative RT–PCR.
The pathological and clinical parameters as well as the percentage
of tumour cells in the individual samples as determined
histologically are summarised in Table 1. As depicted in Figure 1,
prostein mRNA was detected in all tested normal prostate tissue
samples, in the corresponding tumours with different degrees of
progression and in the PCa cell line LNCaP. The expression level of
prostein was highly variable among the patients. In 13 out of 15
patients, prostein transcripts were found at higher or similar levels
in the tumour samples when compared with the corresponding
nonmalignant tissues (Figure 1A), demonstrating that prostein
expression is maintained or even upregulated in the great majority
of tumourous tissues. The mean value of all ratios of prostein
expression in the tumourous tissue to that in the corresponding
nontumourous tissue (T/NT ratio) was 1.82. When the samples
were classified according to the pathological stage and grade, we
found higher mean T/NT ratios in tumours of early stages and
lower grades (Table 2). Owing to the high variability among the T/
NT ratios of the individual samples with the same pathological
features and a similar percentage of tumour cells, this correlation
was not statistically significant (unpaired Student’s t-test).
Furthermore, no correlation between the Gleason score of the
tumours and the T/NT ratios was determined (Table 2).
Following the observation by Xu et al (2001) that prostein
expression is regulated by androgens, the androgen-responsive
PCa cell line LNCaP 1740 was grown in medium containing FCS
that was depleted of androgens by charcoal stripping or in the
same stripped medium supplemented with the synthetic androgen
R1881 and then used for the quantification of prostein transcripts.
As depicted in Figure 1B, the prostein mRNA expression was
downregulated but still detectable under conditions of androgen
deprivation when compared with LNCaP cells cultured in the
presence of R1881.
Selection of HLA-A*0201-binding peptides
Using a suited algorithm, the amino-acid sequence of prostein was
screened for peptides predicted to bind to HLA-A*0201, the most
common HLA class I allele in Caucasian individuals (Table 3).
Peptides that effectively bind to HLA-A*0201 are usually nonamers
or decamers with the typical anchor position isoleucine (I) or
leucine (L) at position 2 and valine (V), leucine (L) or methionine
(M) as the C-terminal residue. The six highest scoring peptides,
fulfilling these criteria, were synthesised and analysed for their
binding affinity to HLA-A*0201 by a competition assay using
peptide YLLPAIVHI from RNA helicase p72 as positive control
and peptide ILK(FITC)EPVHGV from HIV-1 reverse transcriptase
as reporter peptide. Binding affinities were classified as strong
when the binding of a reporter peptide was inhibited by 75–100%,
related to the inhibition of reporter peptide binding by a positive
control peptide or as intermediate when the inhibition was 50–
75%. The peptides 1472, 1479, 1487, 1494 and 2004 bound with
high affinity, whereas peptide 1478 showed an intermediate affinity
(Table 3). All six peptides were used for the in vitro stimulation of
CD8þ T lymphocytes.
In vitro generation of prostein peptide-specific and
tumour-reactive CD8þ cytotoxic effector cells
CD8þ T lymphocytes isolated from the blood of two prostate
cancer patients (donors 1 and 3) and one healthy donor (donor 2)
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of the peptides 1478, 1479 and 2004. CD8þ T cells from the same
healthy donor (donor 2) and an additional patient (donor 4) were
subjected to stimulations with a cocktail of the peptides 1472, 1487
and 1494. After four stimulation cycles, T cells were tested for the
presence of peptide-specific CTLs by chromium release assays.
Only peptide 2004 induced specific CTLs in all three donors
tested (donors 1–3) as shown by the specific lysis of T2 cells
loaded with this peptide (Figure 2). Unloaded T2 cells and T2 cells
pulsed with an irrelevant peptide from HIV reverse transcriptase
were only marginally lysed (Figure 2). To determine whether
peptide 2004 originates from intracellular processing of the
prostein protein and is presented on the surface of tumour cells,
the peptide-specific T cells were tested against the prostein-
positive PCa cell line LNCaP 1740. This cell line expresses HLA-A2
molecules at a low density on the cell surface as demonstrated by
flow cytometric analysis using the anti-HLA-A2 antibody MA2.1
(Figure 3A). The melanoma cell line 93.04A12.1, which is negative
for prostein transcripts (Figure 1A) but expresses HLA-A2 at a
much higher level than LNCaP 1740 cells (Figure 3B), was used as a
negative control. The T-cell cultures of all three donors effectively
lysed LNCaP 1740 cells, whereas only marginal lysis of 93.04A12.1
cells was observed (Figure 4A). Natural killer cell-like activity was
excluded by the failure of the peptide 2004-activated T cells to lyse
K562 cells (Figure 4A). As illustrated in Figure 4B, the recognition
of LNCaP 1740 was restricted to HLA-A2 as shown by a significant
reduction of lytic activity in the presence of the anti-HLA-A2
antibody MA2.1.
According to the observation that prostein expression in LNCaP
1740 cells is regulated by androgens (Figure 1B), we evaluated the
cytotoxic activity of the in vitro-generated CD8þ effector T cells
against LNCaP 1740 cells that were cultured in the absence or
presence of androgen. As depicted in Figure 4C, the T-cell-
mediated cytotoxicity of all three donors against target cells
deprived of androgen was clearly reduced when compared with the
lysis of LNCaP 1740 cells grown in the presence of R1881.
DISCUSSION
Recently, prostein was identified as a novel protein with a unique
specificity for normal and malignant prostate tissues as demon-
strated by quantitative RT–PCR, Northern blot and cDNA
Table 2 Association of tumour stage and grade with the expression level of prostein mRNA as determined by quantitative RT–PCR
Tumour stage Gleason score Tumour grade
pT2 (n¼8) pT3 (n¼4) pT4 (n¼3) p7( n¼9) X7( n¼5) IIa, Iib (n¼7) IIIa, IIIb (n¼6)
T/NT ratio
a 2.05 1.98 0.97 1.78 1.72 1.85 1.32
aMean value of the individual ratios of transcript quantity in the tumourous samples (T) to that in the corresponding nontumourous tissues (NT) when classified according to
pathological stages and grades. n¼number of paired tissue samples; RT–PCR¼reverse transcription–PCR.
Figure 1 Real-time PCR analysis of prostein mRNA expression in
matched samples of malignant and nonmalignant prostate tissues, in the
PCa cell line LNCaP 1740, and the melanoma cell line 93.04A12.1. (A)T o
quantify the prostein mRNA expression in 15 paired cDNA samples of
tumourous (black bars) and nontumourous (white bars) prostate tissues
and in LNCaP 1740 and 93.04A12.1 cells a 240bp fragment was amplified
in a SYBR Green I-based LC assay. The transcript quantity was normalised
to the expression level of HPRT. The results represent the means of two
LC runs, bars indicate s.e. The ratio of prostein expression in the
tumourous related to the transcript quantity in the corresponding
nontumourous tissue sample (ratio T/NT) is given for each tissue pair.
Patients’ data were classified according to their tumour stage (pT) and
within the groups according to the T/NT ratios. (B) The PCa cell line
LNCaP 1740 was cultured for 48h in the androgen-depleted medium
(LNCaP a) or in the presence of 1nM of the synthetic androgen R1881
(LNCaP b) and then used for RNA preparation and quantification of
prostein transcripts. The results represent the means of two LC runs, bars
indicate s.e.
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chemical analysis at the protein level (Xu et al, 2001). Whereas Xu
et al determined prostein expression in a collection of PCa tissues
and normal prostate samples, we expanded this study by using
matched pairs of tumourous and nontumourous prostate tissue for
the mRNA quantification. Transcripts were abundant in both
malignant and nonmalignant prostate tissues. Therefore, prostein
like most of the so far described PCa-associated proteins is a
tissue-restricted yet not tumour-specific molecule (Hubert et al,
1999; Nelson et al, 1999; Lin et al, 2000; Naz et al, 2002; Herness
and Naz, 2003). When comparing the transript levels of prostein in
the malignant tissues with the corresponding nontumourous
samples, we found that prostein expression is not reduced in
PCa tissues. This is an important prerequisite for molecules that
are supposed to serve as a target structure for immunotherapy.
In recent years, HLA allele-specific peptides from a limited
number of well-characterised prostate-associated antigens includ-
ing PSA (Correale et al, 1998), prostate-specific membrane antigen
(Tjoa et al, 1996; Horiguchi et al, 2002), prostate acid phosphatase
(Peshwa et al, 1998; Inoue et al, 2001) and prostate stem cell
antigen (Kiessling et al, 2002) have been identified as target
structures of CTLs. These studies have clearly demonstrated that
the immune tolerance against self-proteins expressed in normal
prostate tissue can be overcome. In addition, clinical PCa
responses have been described in vaccination studies based on
CD8þ effector T cells targeting different TAAs (Murphy et al,
1999; Small et al, 2000). However, the heterogeneity of individual
tumours (Klein et al, 2002) and the diversity of tumour escape
mechanisms (Marincola et al, 2000) require the identification of
additional target structures for T-cell-based immunotherapy.
The highly prostate-specific expression of prostein suggested
extended evaluation of this protein for this form of immuno-
therapy. To identify CD8þ T-cell epitopes from prostein, six
HLA-A*0201-binding peptides were predicted from the amino-
acid sequence of prostein by a computer-based algorithm. For
each of the peptides HLA-A*0201 binding was verified by a
competition assay. Of this collection, only peptide 2004 (CLAA-
GITYV) encompassing the amino-acid residues 31–39 of prostein
was able to induce specific CTLs in vitro when tested against
peptide-loaded T2 cells. The lack of response to the other five
peptides may indicate a low frequency or even absence of T cells
displaying the respective specificities in the repertoire of the tested
donors.
The CTLs specifically recognising peptide 2004 on T2 cells were
also capable of lysing the HLA-A*0201-positive and prostein-
expressing PCa cell line LNCaP 1740, demonstrating the auto-
chthonous generation and presentation of this peptide by tumour
cells. The prostein specificity and HLA-A2 restriction of LNCaP
1740 cell lysis was supported by different control experiments: (a)
neither the natural killer cell-sensitive cell line K562 nor the HLA-
A*0201-positive and prostein-negative melanoma cell line
93.04A12.1 was killed. (b) The lysis of LNCaP 1740 was markedly
reduced in the presence of the anti-HLA-A2 antibody MA2.1.
The studies of Xu et al (2001) have clearly shown for both the
transcript and the protein level that prostein is an androgen-
regulated molecule. Here, we demonstrate that the killing of
LNCaP 1740 cells by CTLs specifically recognising peptide 2004 is
reduced when the target cells are grown in androgen-deprived
medium and can be increased when the medium is supplemented
with androgen. This effect can be explained by the androgen-
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Figure 2 In vitro generation of cytotoxic effector T cells specifically
recognising the prostein-derived peptide 2004. Purified CD8þ T
lymphocytes of two prostate cancer patients (donors 1 and 3) and one
healthy donor (donor 2) were weekly stimulated by peptide-pulsed
autologous DCs. After four stimulations T-cell cultures were tested for the
activation of peptide-specific tumour-reactive CTLs. The stimulated T-cell
cultures were added to 3 10
3 peptide-pulsed T2 target cellswell
 1 at an
effector cell to target cell ratio of 20:1. Unloaded T2 cells and T2 cells
pulsed with an irrelevant peptide from HIV reverse transcriptase served as
controls. The results represent the mean values of triplicate determinations,
bars indicate s.e.
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Figure 3 HLA-A2 expression on the surface of the tumour cell lines used as target cells in the chromium release assays. The PCa cell line LNCaP 1740
(A), the melanoma cell line 93.04A12.1 (B) and the HLA-A2-negative PCa cell line PC-3 as control (C) were analysed by flow cytometry using the anti-
HLA-A2 antibody MA2.1 as primary antibody and a PE-labelled goat anti-mouse IgG F(ab0)2 fragment as secondary antibody. The solid line represents the
IgG1 isotype control, the shaded peak represents the HLA-A2 staining.
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yregulated expression level of prostein that may directly influence
the density of the respective HLA class I peptide complex on the
surface of the LNCaP 1740 cells.
In summary, we identify an HLA-A*0201-restricted CD8þ T
cell epitope derived from the prostate-specific protein prostein
that was shown to be widely expressed in PCa. Our results
emphasise this protein as a target molecule to be included in
immunotherapeutic trials of PCa.
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Figure 4 Prostein-specific lysis and HLA-A*0201-restricted recognition of LNCaP 1740 cells by the in vitro-generated cytotoxic effector cells. (A) After
four rounds of stimulation activated CD8þ T cells from the three donors were cocultured with 3 10
35 1 Cr-labeled LNCaP 1740, 93.04A12.1 or K562
tumour cellswell
 1 at various effector cell (E) to target cell (T) ratios (3:1, 10:1, 30:1). After 4h of incubation, chromium release was determined. (B) The
inhibition of T-cell-mediated cytotoxicity against LNCaP 1740 cells was tested in the presence of the monoclonal anti-HLA-A2 antibody MA2.1 at an E:T
ratio of 30:1. (C) Influence of androgen deprivation or supplementation on the prostein-specific lysis of LNCaP 1740 target cells. LNCaP 1740 cells were
cultured for 24h in medium containing charcoal-stipped FCS. Cells were grown for additional 48h in the androgen-deprived medium or in the presence of
1n M R1881 and then used as target cells in a chromium release assay at an E:T ratio of 30:1. All results represent the mean values of triplicate
determinations, bars indicate s.e.
Table 3 Prediction of HLA-A*0201-restricted prostein-derived peptides and determination of binding affinity by a competition assay
Peptide Position
a Sequence MW Length
b Score rBA (%)
c
1472 394–402 ILPYTLASL 989.6 9 29 87.5
1478 452–460 GLLPPPPAL 873.5 9 28 55.0
1479 393–402 QILPYTLASL 1117.6 10 30 92.6
1487 255–263 ALLPRLHQL 1059.7 9 31 84.1
1494 507–516 SLFMGSIVQL 1093.6 10 29 89.2
2004 31–39 CLAAGITYV 909.5 9 28 94.0
aThe given numbers indicate the position of the peptide in the amino-acid sequence of prostein (GenBank accession no. NP_149093).
bNumber of amino acids.
cThe relative
binding affinities were determined by comparing the inhibition of the reporter peptide binding by the analysed peptides in relation to the inhibition obtained with a positive
control peptide which was set as 100%. The positive control peptide was YLLPAIVHI from RNA helicase p72 and the reporter peptide was ILK(FITC)EPVHGV from HIV-1
reverse transcriptase. All peptides were used at a concentration of 10mM. rBA, relative-binding affinity; MW, molecular weight; HLA¼human leucocyte antigen.
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